NasdaqHealth CareHealth Care ServicesS&P SmallCap 600
$24.16
+0.16 (+0.67%)
Close of Nov 06, 2026 · end-of-day data
VCYT 8-K filings, explained
Every material Form 8-K Veracyte has filed with the SEC since August 06, 2024, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Veracyte reported third-quarter 2026 total revenue of $151.8 million, up 15% from a year earlier, and GAAP net income of $31.5 million, or $0.38 per diluted share. The company lowered its 2026 testing revenue guidance to $571 million to $573 million from $576 million to $582 million, and cut the top of its total revenue range to $590 million to $593 million from $590 million to $596 million. The board also authorized a share repurchase program of up to $100 million over 12 months.
Q3 2026 total revenue $151.8 million, up 15%; Decipher Prostate $92.3 million and Afirma $51.5 million
GAAP diluted EPS $0.38 vs. $0.24 a year earlier; non-GAAP diluted EPS $0.51, flat year over year
2026 testing revenue guidance cut to $571 million to $573 million from $576 million to $582 million
Board authorized buyback of up to $100 million over 12 months; cash and short-term investments were $370.5 million at September 30, 2026
Veracyte, Inc. completed its acquisition of Convergent Genomics on September 14, 2026, through a merger under an agreement signed September 10, 2026, adding the UroAmp urine tumor DNA platform for bladder cancer. The filing states the company did not update its previously provided 2026 adjusted EBITDA guidance, which already contemplated Convergent's operating expenses, and no financial results for Convergent were disclosed.
Upfront cash consideration of $150 million, subject to customary purchase price adjustments
Up to $30 million in additional cash tied to UroAmp publication and reimbursement milestones
Merger agreement dated September 10, 2026; closing completed September 14, 2026
Veracyte expects to commercialize its first UroAmp-based test in late 2028, subject to reimbursement timelines
Veracyte reported second-quarter 2026 total revenue of $150.3 million, up 15% from a year earlier, and GAAP net income of $25.5 million, or $0.31 per diluted share, compared with a net loss of $980,000 a year earlier. The company raised its 2026 total revenue guidance to $590 million to $596 million, which signals stronger expected growth for shareholders.
Total revenue rose 15% to $150.3 million; testing revenue rose 19% to $145.7 million
GAAP net income was $25.5 million, or $0.31 per diluted share, versus a net loss of $980,000 in Q2 2025
2026 total revenue guidance raised to $590 million to $596 million from $582 million to $592 million
Cash, cash equivalents and short-term investments totaled $485.2 million as of June 30, 2026
At its June 10, 2026 annual meeting, Veracyte stockholders approved an amendment adding 3,500,000 shares to the 2023 Equity Incentive Plan, and elected all nine director nominees. Stockholders also ratified Ernst & Young LLP as the independent auditor for 2026 and approved executive compensation on an advisory basis. The larger share reserve gives the company more room to grant equity awards, and the plan vote drew 21,060,296 votes against.
Stockholders approved adding 3,500,000 shares to the 2023 Equity Incentive Plan: 52,059,077 for, 21,060,296 against.
All nine director nominees, including Eliav Barr and Brent Shafer, were elected to serve until the 2027 annual meeting.
Ernst & Young LLP was ratified as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
The Board approved the plan amendment on April 8, 2026, subject to stockholder approval.
Veracyte reported first-quarter 2026 total revenue of $139.1 million, up 21% from a year earlier, and GAAP net income of $28.7 million, compared with $7.0 million in the first quarter of 2025. The company raised its 2026 total revenue guidance to $582 million to $592 million and its adjusted EBITDA margin guidance to greater than 26%, which shareholders may view as a sign that growth is running ahead of earlier expectations.
Total revenue was $139.1 million, up 21% from $114.5 million; testing revenue was $135.1 million, up 26%.
GAAP net income was $28.7 million, or $0.35 per diluted share, versus $7.0 million, or $0.09 per diluted share, a year earlier.
2026 total revenue guidance was raised to $582 million to $592 million from $570 million to $582 million.
Adjusted EBITDA margin guidance was raised to greater than 26% from approximately 25%.
Veracyte reported fourth-quarter 2025 total revenue of $140.6 million, up 19% from a year earlier, and GAAP net income of $41.1 million, or $0.51 per diluted share, compared with $5.1 million, or $0.06, in the prior-year quarter. The company also reiterated its 2026 total revenue guidance of $570 million to $582 million, which shows results improved and the outlook was held steady.
Q4 2025 total revenue was $140.6 million, up 19% from $118.6 million; testing revenue was $135.8 million, up 21%.
Q4 2025 GAAP net income was $41.1 million, or $0.51 per diluted share, versus $5.1 million, or $0.06, in Q4 2024.
Full-year 2025 total revenue was $517.1 million, up 16%, and GAAP net income was $66.4 million.
The company reiterated 2026 total revenue guidance of $570 million to $582 million (10% to 13% growth) and expects adjusted EBITDA margin of about 25%.
Veracyte preliminarily estimated full-year 2025 total revenue of $515 million to $517 million, up about 16%, and fourth-quarter revenue of $138 million to $140 million. The figures are unaudited and may change when audited results are released, expected in February 2026. The company also initiated 2026 total revenue guidance of $570 million to $582 million, or 10% to 13% growth.
Full-year 2025 testing volume of approximately 169,700 tests, up 19%
Fourth-quarter 2025 total revenue of $138 million to $140 million, up 16% to 18% from a year earlier
2026 guidance: total revenue of $570 million to $582 million and adjusted EBITDA margin of 25%
Audited full-year 2025 results to be reported on an earnings call in February 2026
Veracyte reported third-quarter 2025 results on November 4, 2025, with total revenue up 14% to $131.9 million and GAAP net income of $19.1 million, up from $15.2 million a year earlier. The company raised its full-year 2025 total revenue and testing revenue guidance, which signals higher expected sales for shareholders, though GAAP results included a $6.7 million loss tied to the deconsolidation of Veracyte SAS.
Total revenue rose to $131.9 million from $115.9 million; testing revenue rose 17% to $127.8 million.
GAAP net income was $19.1 million, or $0.24 per diluted share, versus $15.2 million, or $0.19, a year earlier; results included a $6.7 million loss from the deconsolidation of Veracyte SAS.
Full-year 2025 total revenue guidance was raised to $506 million to $510 million from $496 million to $504 million.
Adjusted EBITDA was $39.7 million, or 30.1% of revenue, compared with 23.6% a year earlier.
Veracyte reported second-quarter 2025 total revenue of $130.2 million, up 14% year over year, and swung to a GAAP net loss of $1.0 million after a $20.5 million impairment tied to its French subsidiary. The company raised its full-year testing revenue guidance and initiated full-year total revenue guidance of $496 million to $504 million, which matters to shareholders because it signals higher expected sales while the one-time charge weighs on reported profit.
Q2 2025 total revenue was $130.2 million, up 14% from $114.4 million; testing revenue was $122.3 million, up 14%.
GAAP net loss was $1.0 million, compared with net income of $5.7 million in Q2 2024, including a $20.5 million impairment charge.
Full-year 2025 testing revenue guidance was raised to $477 million to $483 million from $470 million to $480 million; total revenue guidance is $496 million to $504 million.
Non-GAAP diluted EPS was $0.44, up from $0.30 a year earlier; adjusted EBITDA was $35.8 million, or 27.5% of revenue.
At its June 17, 2025 annual meeting, Veracyte stockholders approved an amendment adding 2,500,000 shares to the 2023 Equity Incentive Plan and elected all seven director nominees. Stockholders also ratified Ernst & Young LLP as auditor for 2025 and approved future say-on-pay votes every year. The plan amendment passed with 50,604,131 votes for and 19,070,837 against, so the larger share reserve adds potential dilution for existing holders.
Plan amendment adds 2,500,000 shares of common stock to the 2023 Equity Incentive Plan; approved 50,604,131 for, 19,070,837 against, 15,258 abstain
All seven director nominees elected to serve until the 2026 annual meeting
Ernst & Young LLP ratified as independent registered public accounting firm for fiscal year ending December 31, 2025
Stockholders approved holding non-binding say-on-pay votes every year; next frequency vote expected at the 2031 annual meeting
Veracyte reported first-quarter 2025 total revenue of $114.5 million, up 18% from a year earlier, and net income of $7.0 million, compared with a net loss of $1.9 million in the same quarter of 2024. The company reiterated its 2025 testing revenue guidance of $470 million to $480 million and raised its adjusted EBITDA margin outlook to 22.5% from 21.6%, but it also said its French subsidiary Veracyte SAS has entered collective proceedings in a Marseille commercial court and that the parent will no longer fund that entity.
Total revenue $114.5 million, up 18%; testing revenue $107.3 million, up 19%
Net income $7.0 million, or $0.09 diluted per share, versus a net loss of $1.9 million a year earlier
2025 adjusted EBITDA margin guidance raised to 22.5% from 21.6%; testing revenue guidance reiterated at $470 million to $480 million
Veracyte SAS court process expected to finish by end of 2025; the company recorded $3.8 million of related expense in the quarter
Veracyte reported fourth-quarter 2024 revenue up 21% to $118.6 million and full-year 2024 net income of $24.1 million, compared with a net loss in 2023. The company is considering ending funding for its French subsidiary, Veracyte SAS, which could lead to bankruptcy proceedings after a works council consultation unless a buyer is found, and it is not providing total company revenue guidance for 2025.
Q4 2024 total revenue $118.6 million, up 21%; testing revenue $112.2 million, up 24%
Q4 2024 net income $5.1 million, diluted EPS $0.06; full-year 2024 net income $24.1 million, diluted EPS $0.31
2025 testing revenue guidance $470 million to $480 million; no total revenue guidance due to Marseille, France uncertainty
Veracyte SAS may begin bankruptcy proceedings after works council consultation if no funding or buyer is identified
Veracyte reported third-quarter 2024 total revenue of $115.9 million, up 29% from a year earlier, and net income of $15.2 million, compared with a net loss of $29.6 million in the third quarter of 2023. The company raised its full-year 2024 total revenue guidance to $442 million to $445 million, from $432 million to $438 million previously.
Total revenue of $115.9 million, up 29% from $90.1 million; testing revenue of $109.5 million, up 34%
Diluted EPS of $0.19 (GAAP), compared with a loss of $0.41 per share a year earlier; non-GAAP diluted EPS of $0.33
Full-year 2024 total revenue guidance raised to $442 million to $445 million; year-end cash guidance raised to $280 million to $285 million
Third-quarter cash from operations of $30.0 million; cash and cash equivalents of $274.1 million at September 30, 2024
Veracyte's board appointed Tom Miller, Ph.D., and Brent Shafer as directors on September 3, 2024, effective immediately, following a recommendation from the Nominating and Corporate Governance Committee. The filing describes routine board additions with standard director compensation and indemnification terms, and does not disclose any financial results or changes to company operations.
Board appointed Tom Miller, Ph.D., and Brent Shafer as directors on September 3, 2024, effective immediately.
Dr. Miller joins the Regulatory and Compliance Committee; Mr. Shafer joins the Compensation Committee.
Both directors are eligible for the non-employee director compensation program and signed the company's standard indemnity agreement.
Their terms run until the 2025 annual meeting of stockholders or until a successor is elected.
Veracyte reported second-quarter 2024 total revenue of $114.4 million, up 27% from $90.3 million a year earlier, and swung to net income of $5.7 million from a net loss of $8.4 million. The company raised its full-year 2024 total revenue guidance to $432 million to $438 million from $402 million to $410 million, which is a positive signal for shareholders.
Q2 2024 total revenue was $114.4 million, up 27% from $90.3 million in Q2 2023; testing revenue rose 31% to $107.0 million.
Net income was $5.7 million, or $0.07 per diluted share, versus a net loss of $8.4 million, or $(0.12) per share, in Q2 2023.
Adjusted EBITDA was $24.0 million, or 21% of revenue, compared with $11.0 million, or 12% of revenue, a year earlier.
Full-year 2024 total revenue guidance rose to $432 million to $438 million; year-end cash guidance rose to $260 million to $270 million.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Veracyte filing is on SEC EDGAR ↗. 8-K briefs of other companies →